Workflow
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect

Key Takeaways VKTX to report Q2 results on July 23 with no revenue expected and a projected EPS loss of $0.44. Investor focus centers on VK2735's VANQUISH trial enrolment and oral dosing study progress. Updates are also expected on IND filing for DACRA obesity candidate and updates on NASH and X-ALD programs.We expect investors to focus on updates related to Viking Therapeutics’ (VKTX) pipeline when it reports second-quarter 2025 results on July 23, after market close. In the last reported quarter, the co ...